DAX+0,95 % EUR/USD-0,08 % Gold-0,12 % Öl (Brent)+0,76 %

BioNTech - Ein deutscher Biotech-Riese erwacht (Seite 12)

Begriffe und/oder Benutzer


BioNTech präsentiert am 14.11.2019 (zum 1.Mal) Zahlen und corporate update.

"... will announce on Thursday, November 14th, 2019 its financial results for the third quarter ended September 30, 2019. BioNTech will also host a conference call and webcast on the same day at 08:00 a.m. ET (2:00 p.m. CET) to report its financial results for the third quarter ended September 30, 2019 and provide a corporate update."

BioNTech | 16,40 €
Özlem Türeci, die CMO von BioNTech hat es schon in die Liste der "Twenty extraordinary women in biopharma R&D..." geschafft.

BioNTech | 17,90 €
Antwort auf Beitrag Nr.: 61.902.857 von questionmark am 12.11.19 16:53:28heute ist echt viel Bewegung drin. Ich habe hin und her überlegt aber vorhin nun nachgekauft.
BioNTech | 17,37 $
Antwort auf Beitrag Nr.: 61.903.940 von Dealmaker2019 am 12.11.19 18:18:21...ohne "e" :)
BioNTech | 17,92 $
BioNTech SE Provides Update on Corporate Progress and Third Quarter 2019 Financial Results


"Successfully transferred IND for BNT321 to BioNTech. All necessary safety and other reports and an updated protocol filed with the FDA. Phase 1/2 trial of BNT321 expected to be re-initiated in the fourth quarter of 2019.

Initiated a first-in-human global Phase 1/2a trial in collaboration with Genmab for GEN1042 (BNT312), a bispecific antibody targeting CD40 and 4-1BB for the treatment of multiple solid tumors.

Entered into a clinical trial supply agreement with Regeneron to supply cemiplimab for use in combination with BioNTech’s BNT112 in a first-in-human Phase 1/2 trial of FixVac in advanced prostate cancer and received approval of clinical trial applications (CTAs) in various European countries to support the initiation of this trial.

Filed IND for BNT411. Phase 1/2a clinical trial of BNT411 expected to be initiated as a mono- or combination therapy in solid tumors in the first half of 2020.

The selective toll-like receptor 7 agonist has shown activity in numerous mouse tumor models, such as reduced tumor growth and tumor clearance.

Ended the third quarter of 2019 with cash equivalents of $505m (€463.3m1).

Raised additional $149m (approx. €135m) in net proceeds (after underwriting discounts and commissions) in Nasdaq IPO in October/November 2019.

Conference call and webcast (in English) scheduled for November 14, 2019 at 08:00 a.m. ET
(2:00 p.m. CET)"

BioNTech | 17,65 €
Antwort auf Beitrag Nr.: 61.922.945 von RichyBerlin am 14.11.19 15:26:00
Q3 Zahlen
BioNTech Q3:
121 Mio. € Verlust in 9 Monaten!
Im IPO Prospekt stand noch was von größeren Investitionen an 2 Standorten im dreistelligen Millionenbereich. Respekt!
BioNTech | 18,90 $

Beitrag zu dieser Diskussion schreiben